---

​Vital Connect offers a differentiated wearable sensor technology that allows for continuous, real-time cardiac arrhythmia detection while simultaneously measuring patient physiological parameters. The Company’s platform offers physicians a single multi-modal device, multi-parameter monitoring, and real-time 24/7 access to data. Vital Connect leverages its extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms to achieve better clinical and economic outcomes.

Vital Connect products are designed for use in a broad range of inpatient and outpatient settings, including hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. In December 2021, EW was the lead investor in a ~$40 million growth equity financing round in Vital Connect to support the Company’s growing commercial efforts and further product development.

• San Jose, CA


• Contact:
  Bob White
  Shaunak Parikh
  

Related News

• VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
• Frost & Sullivan Recognizes VitalConnect with the 2022 New Product Innovation Award for Its Leading-edge Wearable Patient Monitoring Device
• VitalConnect Announces Investment from HCA Healthcare to Accelerate Commercial Growth and Create Strategic Partnership
• VitalConnect Appoints Amy Covert as Chief Financial Officer
• VitalConnect Announces Addition of Heather Getz to Board of Directors
• VitalConnect Announces Closure of $39 Million Round of Growth Financing